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Abstract
Current dogma suggests that tumor-reactive IFN-γ–producing (TH1-type) T-cells are beneficial to patient outcome; 
however, the clinical consequence of these responses with respect to long-term prognosis in colorectal cancer (CRC) is 
not understood. Here, we compared the utility of preoperative, peripheral blood–derived IFN-γ+ T-cell responses specific 
to carcinoembryonic antigen (CEA), 5T4, or control antigens (n = 64) with tumor staging and clinical details (n = 87) in 
predicting five-year outcome of CRC patients who underwent resection with curative intent. Although disease recurrence 
was more likely in patients with stage III tumors, the presence of preoperative, CEA-specific IFN-γ–producing T-cells 
identified patients at a statistically significantly greater risk of tumor recurrence following surgical resection, irrespective 
of tumor stage (odds ratio = 5.00, 95% confidence interval = 1.96 to 12.77, two-sided P <.001). Responses to other antigens, 
including 5T4, did not reflect outcome. Whilst these results initially appear surprising, they could improve prognostication 
and help redirect adjuvant treatments.
Colorectal cancer (CRC) accounts for more than 600 000 deaths 
per year worldwide (1). Where possible, resection of the pri-
mary tumor is performed with curative intent; however, 40% 
to 50% of these patients will relapse or die from metastatic 
disease (2). The current benchmark for predicting survival 
and guiding treatment is clinicopathological staging of the 
excised tumor. Patients with a Tumor-Node-Metastasis (TNM) 
stage I  tumor have a predicted five-year survival of greater 
than 90%; stage II tumor, approximately 70% to 85%; stage III 
tumor, approximately 40% to 55%; and stage IV tumor, less 
than 10% (3).
TH1-type (IFN-γ–producing) CD4
+ and CD8+ T-cells, which 
recognize tumor antigens, may play a critical role in antitu-
mor immunity, as illustrated by adoptive transfer of T-cells into 
cancer-bearing recipients (4–6). The presence of tumor-specific 
T-cells is not always conducive with beneficial outcome: An 
increased pretreatment frequency of MART1- and NY-Eso-1–
specific CD8+ T cells in melanoma patients receiving anti–PD-1 
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treatment was associated with a poorer outcome. Whether 
these T-cells produced IFN-γ is not clear (7). We have previously 
identified peripheral blood-derived T-cell responses in preopera-
tive CRC patients specific to the tumor-associated antigens car-
cinoembryonic antigen (CEA), an autoantigen expressed at low 
levels in normal intestinal epithelia (8,9), and 5T4, an oncofetal 
antigen that is not expressed in healthy adult tissues (10,11). 
Both proteins are markedly upregulated in most CRCs, how-
ever the clinical significance of tumor-specific vs autoantigen-
specific T-cell responses with respect to long-term prognosis is 
not understood. For some individuals, these responses are only 
measurable after in vitro depletion of regulatory T-cells (Tregs), 
which suppress antitumor immunity (10,12,13).
Here, we present the clinico-demographic details of 87 
patients, recruited to a single center, undergoing an intended 
curative resection of primary CRC (TNM stage I-III). Patients 
gave written informed consent and were followed for up to five 
years (clinical details shown in Supplementary Table 1, available 
online); the Cardiff and Vale University ethics committee granted 
approval for this study. Immune responses were measured in 64 
patients, where blood was available for experiments, allowing an 
analysis of whether immunological characteristics correspond 
to outcome. IFN-γ–producing T-cell responses to tumor antigens 
(CEA, 5T4) and control antigens (PPD, HA) were enumerated by 
ex vivo ELISpot as described (10,12). Briefly, unmanipulated or 
CD25hiCD4+ (>90% Foxp3+) Treg-depleted peripheral blood mono-
nuclear cells were stimulated with either 1 μg/mL CEA, 5T4, PPD, 
HA, or media alone, in anti-IFN-γ–coated ELISpot plates (MabTech 
AB, Sweden). Following incubation, plates were developed 
and spots (ie, activated antigen-specific T-cells) counted using 
an automated plate reader (A.I.D. GmbH, Germany); positive 
responses were defined as described (Supplementary Figure  1, 
available online). All statistical tests were two-sided, and a P 
value of less than .05 was considered statistically significant.
During the five-year follow-up period, 33 patients died: 25 
because of CRC, five because of unrelated causes, and three 
because of unknown causes. There was little difference (P = .38) 
between overall and disease-free survival (Supplementary 
Figure  2A, available online), indicating that tumor recurrence, 
determined by clinical examination and imaging (CT and/or colo-
noscopy), was mainly responsible for mortality. As expected, like-
lihood of five-year tumor recurrence steadily increased from TNM 
stage I (18.2%), stage II (33.3%) to stage III tumors (51.4%), with a 
statistically significant increase in five-year tumor recurrence in 
stage III patients (hazard ratio [HR] = 2.43, 95% confidence interval 
[CI] =1.12 to 5.30, two-sided log-rank test P = .04) (Supplementary 
Figure 2B, available online). Age, anatomical location of the tumor, 
and gender did not influence the rate of recurrence as deter-
mined by univariate and multivariable analyses (P = .99, .29, and 
.44, respectively) (Supplementary Figure 2, C-F, available online).
IFN-γ+ T-cell responses of different antigen specificity were 
associated with five-year patient survival. The Kaplan-Meier 
curves (Figure 1, A-D) reveal that the presence or absence of CEA-
specific TH1 responses, identified either before or after Treg deple-
tion, statistically significantly distinguish patients most likely to 
suffer tumor recurrence, even at an early time point (log-rank test 
P = .002). In contrast, the presence or absence of responses to 5T4 
(P =  .98) and the control antigens PPD (P =  .66) and HA (P =  .84) 
did not associate with tumor recurrence. However, removing 
5T4-responsive patients from those CEA-responders reveals a 
worsening of survival (P < .001), suggesting benefit in anti-5T4 
immune responses in this subgroup (Figure 1, E-F).
The association of CEA-specific T-cell responses and poor 
outcome remains when patients are stratified by tumor stage 
(Figure  2A). Strikingly, tumor recurrence was more likely in 
stage I/II patients with a CEA-specific response than stage III 
patients with no CEA-specific response. When these responses 
were further stratified on a Forest plot, there was a consistency 
Figure 1. Tumor status compared with preoperative T-cell responses to four distinct antigens. T-cell responses were measured by ex vivo IFN-γ ELISpot to the con-
trol antigens tuberculin purified protein derivative (PPD) (A), haemagglutinin (HA) (B), and the tumor antigens 5T4 (C) and CEA (D), before and after the depletion of 
CD4+CD25hi regulatory T cells from freshly isolated peripheral blood mononuclear cells. Patients were grouped according to the presence or absence of a measured 
T-cell response, and this was associated with survival over five years following initial tumor resection. The outcome of patients who did not produce a measureable 
T-cell response to CEA, either before or after Treg depletion, was compared with those patients who did mount an anti-CEA T-cell response, minus the patients who also 
responded to 5T4 (E). The effect of producing an anti-5T4 T-cell response amongst CEA responders was also associated with survival (F). Statistically significant differ-
ences are indicated (**P < .01, ***P < .001). All statistical tests were two-sided. For the numbers of patients at risk for each group in the curves, please see Supplementary 
Table 2 (available online). CEA = carcinoembryonic antigen; PPD = purified protein derivative.
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of effect over all tumor stages (Figure 2B: odds ratio [OR] = 5.00, 
95% CI = 1.96 to 12.77, P < .001). Despite limited power, tests for 
trend and heterogeneity revealed no evidence of heterogeneity 
of effect by tumor stage (P = 1.0). Furthermore, in a multivari-
able Cox model, the quantitative measure of each patients’ CEA+ 
T-cell response was the most powerful prognostic factor when 
assessing all covariables (P = .004 for entry); after adjustment for 
this in the model, only TNM status was statistically significant at 
P < .05 (Supplementary Figure 2F, available online). Assumptions 
of proportionality were determined and satisfied by examina-
tion of log (-log) survival vs log (time) plots (data not shown). In 
a model with these two variables fitted and using bootstrapping 
with 1000 iterations, the hazard ratio for CEA+ T-cell response 
was 1.04 (95% Wald CI = 1.02 to 1.06) and for the hazard ratio 
for TNM status was 2.30 (95% Wald CI = 1.07 to 4.96) (data not 
shown, results from the bootstrapping analysis). Consistent 
with the results of Figure  2, A and B, whilst power is limited, 
there was no evidence of interaction between CEA response and 
TNM status (P = .99) (data not shown). These data strongly imply 
that the presence (and to a lesser degree magnitude) of CEA-
specific T-cell responses preoperatively are detrimental to post-
surgical outcome and are far more statistically significant than 
tumor stage in identifying patients with disease recurrence.
Currently there is much interest in targeting CEA via antican-
cer vaccination or T-cell–directed adoptive transfer (14,15), thus 
our findings open up debate about the potential risks of such 
strategies in certain situations. Why should CEA-specific, but 
not 5T4-specific, responses be detrimental? There are data dem-
onstrating that adoptive transfer of CEA-specific T-cells to con-
trol CRC induces enteropathy in normal colonic tissue (16,17). It 
is possible that a loss of mucosal integrity with increased epi-
thelial leakiness facilitates tumor growth or recurrence (18,19).
Additionally, upon examination of primary tumor samples 
from the cohort described herein, intratumoral T-cells were 
dominated by the expression of the transcription factor RORγT+, 
a marker for TH17 cells; however, this preponderance of RORγT
+ 
T-cells within tumors was found in both CEA responders and 
nonresponders (Supplementary Figure 3, available online). The 
dominance of TH17 type cells in all patient groups is unexpected. 
We have optimized peripheral blood assays for measuring IL-17 
responses, but as part of an ongoing study in a new group of CRC 
patients, peripheral blood–derived CEA-specific IL-17–producing 
T-cells are observed in less than 5% of patients (data not shown). 
The relationship between blood-derived and tumor-derived 
antigen-specific T-cell responses awaits further investigation.
CEA-specific T-cell responsiveness could also reflect more 
advanced tumor stages, ie, presence of micrometastases that are 
not demonstrated by conventional staging techniques. Whilst 
further studies are required to uncover why CEA-specific T-cells 
confer harm, it is clear that measuring these responses could 
offer crucial prognostic information independent of tumor stage 
and help identify patients at risk for tumor recurrence. Although 
this particular study was limited by the relatively small sample 
size without a validation cohort and by the fact that immunolog-
ical data were not available for all patients, the conclusions from 
this study raise the possibility that targeting adjuvant treatments 
at CEA+ T-cell responders may improve treatment outcome.
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Figure 2. CEA-specific T-cell responses and tumor recurrence. Irrespective of the tumor stage, patients producing an anti-CEA IFN-γ+ T-cell response were more likely 
to suffer a tumor recurrence, as demonstrated in the Kaplan-Meier curve (A) and the Forest plot (B). The statistically significant difference is indicated (**P < .01). All 
statistical tests were two-sided. For the numbers of patients at risk for each group in the curves please see Supplementary Table 2 (available online). CEA = carcinoem-
bryonic antigen; CI = confidence interval; OR = odds ratio; TNM = Tumor-Node-Metastasis.
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